WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 2-Jul-2015 (Data received as of 26-June-2015)
Next overall update Mid July 2015
2014 data are provisional
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 25'9201 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 33'1401 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 49'512  49'263  49'003  48'733  48'454  45'977  42'972  37'451 
Births 474  472  470  468  465  540  670  813 
Surviving infants 472  471  469  466  463  537  662  789 
Pop. less than 5 years 2'367  2'362  2'349  2'310  2'237  3'129  3'241  3'836 
Pop. less than 15 years 7'179  7'335  7'519  7'704  7'870  9'636  11'014  12'703 
Female 15-49 years 12'645  12'739  12'812  12'879  12'948  13'153  12'282  9'885 

Number of reported case

(Click for retrospective incidence data for Republic of Korea (the))
Diphtheria 51 
Japanese encephalitis 26  14  20  26 
Measles 442  107  42  114  32'647  3'415  5'097 
Mumps 17'022  7'147  6'241  6'104  3'057 
Pertussis 76  36  230  97  18  28  174  1'554 
Polio* 14 
Rubella 11  17  27  53  21  153 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)** 26  22  17  19  14 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Republic of Korea (the))
Vaccine year result method % card seen                                                
BCG          99*  99*  99*  99  96  73  72 
DTP1          99*  99*  99*  99*  96  97 
DTP3          99*  99*  99*  99  94  97  74  70 
HepB_BD          92  95  93 
HepB3          99  99  99  99  94  93 
Hib3          97 
JapEnc          99  99  99  98  89 
MCV          99*  99*  99  99  98  95  93 
MCV2          96  95  97  98  98  39 
PCV1         
PCV3         
Pol3          99  99  99  98  95  99  74  89 
Rota1         
Rota_last         
Rubella1          99*  99*  99  99  98 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Republic of Korea (the))
BCG 99  99  99  96  73  72 
DTP1 99  99  99  96  97  90 
DTP3 99  99  99  94  97  74 
HepB3 99  99  99  94  93 
HepB_BD
Hib3
MCV 99  99  99  98  95  93 
MCV2 95  97  98  98  39 
PCV3
Pol3 99  99  98  95  99  74 
Rota_last

Number of districts in the country 255  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth-1 month; Yes
DTaP 2, 4, 6, 15-18 months; 4-6 years; Yes
DTaPIPV 2, 4, 6 months; 4-6 years; Yes
HFRS 1st contact, +1months; +1 year; Yes high risk group
HIB 2, 4, 6, 12-15 months; Yes
HepA 12-23 months; +6-+12 months; Yes From May 2015
HepB birth; 1, 6 months; Yes
IPV 2, 4, 6 months; 4-6 years; Yes
Influenza_Adult >=Y50 Yes and adults with chronic illness, pregnant women, health care workers, and any other risk group
Influenza_Pediatric 6-59 months; Yes and children with chronic illness
JE_Inactd 12-23 months; +7-+30 days; +12 months; 6, 12 years; Yes
JE_LiveAtd 12-23, 34-35 months; Yes
MMR 12-15 months; 4-6 years; Yes
Pneumo_conj 2, 4, 6, 12-15 months; Yes
Pneumo_ps >=65 years; Yes and High risk groups (children over 2 years)
Td 11-12 years; Yes
Tdap 11-12 years; Yes
Typhoid Yes high risk group
Varicella 12-15 months; Yes

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number   3 years  2008-2012  2008-2012  2008-2012  2008-2012  2008-1012 
Nº of districts with microplans that include activities to raise immunization coverage number 255             

System performance

Total Nº districts in country number 255  254  254    230  270  270 
Nº districts with DTP3 coverage >=80% number 255  270  270 
% of districts with DTP3 coverage >=80% From 0 to 100% 100    100  100 
Nº districts with measles (MCV1) coverage >=95% number 235           
% of districts with MCV1 coverage >=95% From 0 to 100% 92             

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 100        52  48  40 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.